二叶式主动脉瓣疾病的TAVI进展与挑战
本文综述经导管主动脉瓣植入术(TAVI)在二叶式主动脉瓣(BAV)患者中的应用现状。BAV存在不对称钙化、主动脉根部扩张及瓣叶融合模式变异等解剖复杂性,影响瓣膜部署与密封;影像技术、瓣膜设计和手术策略的进步提高了TAVI在BAV中的采用率,但外科主动脉瓣置换在该组中仍占更突出地位,部分因BAV患者被几乎所有既往随机对照试验排除。
要点
- BAV解剖复杂:不对称钙化、主动脉根部扩张和瓣叶融合变异影响TAVI部署与密封。
- TAVI适应症向年轻人群扩展,而年轻人群BAV发生率高于老年人群。
- BAV患者被几乎所有既往随机对照试验排除,支持TAVI的证据有限。
核心结论
- 影像技术、瓣膜设计和手术策略的进步促进了TAVI在BAV患者中的采用,但外科主动脉瓣置换在该组中仍比TAV患者占更突出地位。
研究设计与样本
- 本文为最新综述,旨在全面概述TAVI在BAV患者中的当前格局,包括解剖考量、手术陷阱及新器械迭代带来的结局改善。
主要发现
- BAV的不对称钙化、主动脉根部扩张(BAV主动脉病)和瓣叶融合模式变异可影响瓣膜部署、经导管心脏瓣膜密封和长期耐久性。
- TAVI适应症近期扩展至年轻个体,而年轻人群BAV解剖发生率显著高于老年人群。
- BAV患者被几乎所有既往随机对照试验排除,限制了支持TAVI用于该独特队列的可用证据。
临床怎么用
- 在BAV患者中应用TAVI需综合评估解剖复杂性(钙化模式、根部扩张、瓣叶融合)对瓣膜部署和密封的影响。
- 鉴于随机对照试验证据有限,BAV患者中外科主动脉瓣置换仍应保持更突出地位。
局限性
- BAV患者被几乎所有既往随机对照试验排除,支持TAVI用于该队列的证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transcatheter aortic valve implantation (TAVI) has revolutionized the treatment of patients with severe aortic stenosis (AS). Initially developed for patients with tricuspid aortic valve (TAV) anatomy, the procedural success and expanding indications of TAVI have spurred interest in its application to more complex aortic valve anatomies, such as the bicuspid aortic valve (BAV). The growing interest in this specific sub-set of patients with AS is driven by the recent extension of TAVI indications to younger individuals, who exhibit a notably higher incidence of bicuspid anatomy compared with older populations. Bicuspid aortic valves present distinct anatomical and pathological complexities that pose significant challenges to the conventional TAVI approach. These include asymmetric calcification, aortic root dilation (also known as BAV aortopathy), and variations in cusp fusion patterns, which can affect valve deployment, transcatheter heart valve sealing, and long-term durability. Despite these challenges, advancements in imaging techniques, valve design, and procedural strategies have led to increased adoption of TAVI in BAV patients. However, surgical aortic valve replacement still retains a more prominent role in this group compared with patients with TAVs. This preference is partly due to the exclusion of BAV patients from almost all previous randomized controlled trials, which limits the available evidence supporting the use of TAVI in this unique cohort. This state-of-the-art review aims to provide a comprehensive overview of the current landscape of TAVI in BAV patients, including an analysis of anatomical considerations and procedural pitfalls, as well as outcomes' improvements with new device iterations. It will also explore clinical data, tackling the risks, benefits, and the evolving role of TAVI in this unique patient cohort.
引用
- Barbanti M, Costa G, Windecker S, et al. Bicuspid aortic valve disease: advancements and challenges of transcatheter aortic valve implantation. Eur Heart J. 2025. PMID: 40343748. doi:10.1093/eurheartj/ehaf307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。